文献速递创伤与烧伤复苏、休克与脓毒症重症综合管理与镇静镇痛

活化蛋白C减轻创伤诱导的内皮病:创伤后血栓炎症的潜在治疗

Mitigation of trauma-induced endotheliopathy by activated protein C: A potential therapeutic for postinjury thromboinflammation.
PubMed 文献 · J Trauma Acute Care Surg · 2023-09-21
一句话结论体外实验显示,保留约5%抗凝活性的3K3A-aPC预处理可减轻严重创伤患者血浆诱导的内皮通透性升高。

该研究为体外实验,用电阻抗传感实时测量原代内皮细胞通透性;细胞在创伤血浆(损伤严重度评分>15且碱缺失<-6)刺激前30、60、120、180分钟分别用2 μg/mL的3K3A-aPC预处理,并以凝血酶处理组和未处理组为对照。结果显示,各预处理时间点均减轻创伤血浆诱导的通透性升高,30分钟组AUC较单纯创伤血浆组高(平均差22.12,95%CI 13.75-30.49,p<0.0001),60、120、180分钟组亦均较高(p<0.0001);aPC预处理组Rac1/RhoA活性高于其他各组(p<0.01)。作者认为,3K3A-aPC保留细胞保护功能而仅约5%抗凝功能,可阻断创伤诱导的内皮病效应,是损伤患者血栓炎症失调的潜在治疗。

要点

  • 体外实验中,2 μg/mL的3K3A-aPC在创伤血浆刺激前30分钟预处理,内皮通透性AUC较单纯创伤血浆组高(平均差22.12,95%CI 13.75-30.49,p<0.0001)。
  • 60、120、180分钟预处理组AUC亦均高于单纯创伤血浆组(平均差16.30、19.43、18.65,均p<0.0001)。
  • aPC预处理组Rac1/RhoA活性高于其他所有组(p<0.01)。
  • 3K3A-aPC保留细胞保护功能而抗凝功能仅约5%,作者认为其可能是损伤患者血栓炎症失调的潜在治疗。
  • 证据等级:预后与流行病学;Level III。

适用人群与场景

  • 体外原代内皮细胞实验,刺激物为取自严重创伤患者的离体血浆(损伤严重度评分>15且碱缺失<-6)。

诊断标准与关键阈值

  • 创伤血浆供者条件:损伤严重度评分>15且碱缺失<-6。

处置流程与药物剂量

  • 3K3A-aPC以2 μg/mL浓度在创伤血浆刺激前30、60、120、180分钟加入内皮细胞培养体系。

研究设计与关键结果

  • 研究类型:体外实验,用电极-基底阻抗传感实时测量原代内皮细胞通透性;对照为凝血酶处理组和未处理组。
  • 30分钟3K3A-aPC预处理组AUC高于单纯创伤血浆组(平均差22.12,95%CI 13.75-30.49,p<0.0001)。
  • 60分钟、120分钟、180分钟预处理组AUC亦均高于单纯创伤血浆组(平均差16.30,95%CI 7.93-24.67;19.43,95%CI 11.06-27.80;18.65,95%CI 10.28-27.02;均p<0.0001)。
  • aPC预处理组Rac1/RhoA活性高于其他所有组(p<0.01)。
  • 统计学方法:单因素方差分析后Tukey多重比较检验。

证据类型、等级与局限

  • 证据类型:体外实验。
  • 证据等级:预后与流行病学;Level III。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,3K3A-aPC保留细胞保护功能而仅约5%抗凝功能,可阻断创伤诱导的内皮病效应,是损伤患者血栓炎症失调的潜在治疗。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Activated Protein C (aPC) plays dual roles after injury, driving both trauma-induced coagulopathy (TIC) by cleaving, and thus inactivating, factors Va and VIIIa and depressing fibrinolysis while also mediating an inflammomodulatory milieu via protease activated receptor-1 (PAR-1) cytoprotective signaling. Because of this dual role, it represents and ideal target for study and therapeutics after trauma. A known aPC variant, 3K3A-aPC, has been engineered to preserve cytoprotective activity while retaining minimal anticoagulant activity rendering it potentially ideal as a cytoprotective therapeutic after trauma. We hypothesized that 3K3A-aPC would mitigate the endotheliopathy of trauma by protecting against endothelial permeability.

METHODS: We used electric cell-substrate impedance sensing to measure permeability changes in real time in primary endothelial cells. These were cultured, grown to confluence, and treated with a 2 μg/mL solution of 3K3A-aPC at 180 minutes, 120 minutes, 60 minutes, 30 minutes prior to stimulation with ex vivo plasma taken from severely injured trauma patients (Injury Severity Score > 15 and BD < -6) (trauma plasma [TP]). Cells treated with thrombin and untreated cells were included in this study as control groups. Permeability changes were recorded in real time via electric cell-substrate impedance sensing for 30 minutes after treatment with TP. We quantified permeability changes in the control and treatment groups as area under the curve (AUC). Rac1/RhoA activity was also compared between these groups. Statistical significance was determined by one-way ANOVA followed by a post hoc analysis using Tukey's multiple comparison's test.

RESULTS: Treatment with aPC mitigated endothelial permeability induced by ex vivo trauma plasma at all pre-treatment time points. The AUC of the 30-minute 3K3A-aPC pretreatment group was higher than TP alone (mean diff. 22.12 95% CI [13.75, 30.49], p < 0.0001) (Figure). Moreover, the AUC of the 60-minute, 120-minute, and 180-minute pretreatment groups was also higher than TP alone (mean diff., 16.30; 95% confidence interval [CI], 7.93-24.67; 19.43; 95% CI, 11.06-27.80, and 18.65; 95% CI, 10.28-27.02;, all p < 0.0001, respectively). Rac1/RhoA activity was higher in the aPC pretreatment group when compared with all other groups ( p < 0.01).

CONCLUSION: Pretreatment with 3K3A-aPC, which retains its cytoprotective function but has only ~5% of its anticoagulant function, abrogates the effects of trauma-induced endotheliopathy. This represents a potential therapeutic treatment for dysregulated thromboinflammation for injured patients by minimizing aPC's role in trauma-induced coagulopathy while concurrently amplifying its essential cytoprotective function.

LEVEL OF EVIDENCE: Prognostic and Epidemiological; Level III.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Thielen O, Mitra S, Debot M, et al. Mitigation of trauma-induced endotheliopathy by activated protein C: A potential therapeutic for postinjury thromboinflammation. J Trauma Acute Care Surg. 2023. PMID: 37733304. doi:10.1097/TA.0000000000004142

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。